Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill

Abstract Background Atrial fibrillation (AF) is the most common sustained arrhythmia affecting humans. It is an electrical disturbance that leads to rapid, disorganized, and asynchronous contraction of the atrial muscle. In clinical practice, it accounts for approximately one-third of hospitalizations for cardiac rhythm disturbances. The incidence of AF increases from less than 0.1% per year in those under 40 years old to exceed 1.5% per year in women and 2% per year in men older than 80 years. Aim of the Work: to discuss the effect of variation in amiodarone use (including dosage and duration) on dysrhythmia recurrence in patients with new-onset AF in ICU. Patients and Methods This was a prospective observational study conducted over 6 months, 60 patients who fulfilled inclusion criteria were included in the study divided in two groups according to amiodarone dosage, each group is 30 patients: Group (A): received a loading dose of amiodarone followed by an infusion (1200mg amiodarone). Group (B): received a loading dose of amiodarone not followed by an infusion (300mg amiodarone). Results a significant positive correlation was observed between level of C-reactive protein (CRP) and the rate of AF recurrence. As regard effect of CRP on AF recurrence; in AF recurrent patients, mean is (191±77.3) with range from 15 to 352 which significantly differed from Non-recurrent AF patients, mean is (89±63) with range from 20 to 223 (p value <0.001). AF recurrence was higher in group (B) than group (A),. In group (A) 8 patients had recurrent AF representing 26.7 % and in group (B) 19 patients had AF recurrence representing 63.3% (p value =0.004). Conclusion Patients with new-onset AF in (ICU) who are treated with amiodarone should receive a loading dose, immediately followed by an infusion.

Download Full-text

Abstract 17296: Arrhythmia Recurrence and Subsequent Heart Failure Hospitalization in Atrial Fibrillation Patients Undergoing Catheter Ablation: A Landmark Analysis From the Kansai Plus Atrial Fibrillation (KPAF) Registry

Circulation ◽

10.1161/circ.142.suppl_3.17296 ◽

2020 ◽

Vol 142 (Suppl_3) ◽

Author(s):

Nobuaki Tanaka ◽

KOICHI INOUE ◽

Atsushi Kobori ◽

Kazuaki Kaitani ◽

Takeshi Morimoto ◽

...

Keyword(s):

Heart Failure ◽

Atrial Fibrillation ◽

Catheter Ablation ◽

Large Scale ◽

Multicenter Observational Study ◽

History Of ◽

Group A ◽

Group B ◽

Af Recurrence

Background: Heart failure (HF) is the leading cause of death in patients with atrial fibrillation (AF). Radiofrequency catheter ablation (RFCA) of AF is effective for maintaining sinus rhythm though its impact on heart failure still remains controversial. Purpose: We sought to elucidate whether AF recurrence following RFCA was associated with subsequent HF hospitalizations. Methods: We conducted a large-scale, prospective, multicenter, observational study. A total of 4931 consecutive patients who underwent an initial RFCA for AF with longer than 1-year of follow-up in 26 centers were enrolled (average age, 64±10 years; non-paroxysmal AF, 35.7%). The median follow-up duration was 2.9 years. The primary endpoint was an HF hospitalization more than 1-year after the index RFCA. We compared the patients without AF recurrences (group A) to those with AF recurrences within 1-year post RFCA (group B). Results: The 1-year cumulative incidence of AF recurrences after a single procedure was 30.7% (group A=3418, group B=1513 patients). Group B had a lower body mass index (group A vs. group B,24.1±3.6 vs. 23.8±3.4 kg/m 2 , p=0.014), longer history of AF (1.9 vs. 3.1 years, p<0.0001), higher prevalence of non-paroxysmal AF (32.1% vs. 33.9%, p<0.0001), and valvular heart disease (5.9% vs. 7.8%, p=0.013). They also had a lower ejection fraction (63.7±9.4% vs. 62.8±9.6%, p=0.0043) and larger left atrial dimeter (39.7±6.6 vs. 40.6±7.0 mm, p<0.0001) on echocardiography. Hospitalizations for HF were observed in 57 patients (1.14%) more than 1-year after the RFCA and were significantly higher in group B than group A (group A vs. group B, 0.91% vs 1.72%, log-rank p=0.019). Conclusions: Among AF patients receiving RFCA, those with AF recurrences were at a greater risk of subsequent heart failure hospitalizations than those without AF recurrences. Recognition that AF recurrence following RFCA is a risk factor for a subsequent HF-related hospitalization is appropriate in clinical practice.

Download Full-text

Defibrillation threshold of internal cardioversion prior to ablation predicts atrial fibrillation recurrence

10.22541/au.160640119.95228951/v1 ◽

2020 ◽

Author(s):

kohei sawasaki ◽

Yasuya Inden ◽

natsuko hosoya ◽

masahiro muto ◽

Toyoaki Murohara

Keyword(s):

Atrial Fibrillation ◽

Medical Center ◽

Defibrillation Threshold ◽

Ablation Procedure ◽

Recurrence Rates ◽

Internal Cardioversion ◽

Group A ◽

Group B ◽

Recurrence Method ◽

Af Recurrence

Background: Many studies have reported the predictors of atrial fibrillation (AF) recurrence after persistent AF (peAF) ablation. However, the correlation between the atrial defibrillation threshold (DFT) for internal cardioversion (IC) and AF recurrence rate is little-studied. We investigated the relationship between DFT prior to catheter ablation for peAF and the AF recurrence. Method and Results: From June 2016 to May 2019, we enrolled 82 consecutive patients (mean age 65.0 ± 12.4 years), including 45 patients with peAF and 37 with long-standing peAF, at Hamamatsu medical center. In order to assess the DFT, we performed IC with gradually increasing energy prior to radiofrequency application. Forty-nine and 33 patients showed DFT values less than or equal to 10 J (group A) and greater than 10 J or unsuccessful defibrillation (group B), respectively. During the mean follow-up duration of 20.5 ± 13.1 months, patients in group B showed significantly higher AF recurrence rates than those in group A after the ablation procedure (P = 0.017). Multivariate analysis revealed that the DFT was the only predictive factor for AF recurrence (OR=1.07; 95% CI: 1.00-1.13, P = 0.047). Conclusions: The DFT for IC was one of the strongest prognostic factors in the peAF ablation procedure.

Download Full-text

Pentraxin 3 and other inflammatory biomarkers related to atrial fibrillation in cardiac surgery

Perfusion ◽

10.1177/0267659116679248 ◽

2016 ◽

Vol 32 (4) ◽

pp. 269-278 ◽

Cited By ~ 2

Author(s):

Zdenka Holubcova ◽

Pavel Kunes ◽

Jiri Mandak ◽

Dana Vlaskova ◽

Martina Kolackova ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cardiac Surgery ◽

Serum Levels ◽

Inflammatory Biomarkers ◽

Surgical Patients ◽

Significant Difference ◽

History Of ◽

Group A ◽

Group B ◽

New Onset

Objectives: The aim was to evaluate the association between perioperative inflammatory biomarkers and atrial fibrillation (AF) in cardiac surgical patients. Methods: Forty-two patients undergoing cardiac surgery were divided into three groups according to the occurrence of AF: Group A (n = 22) – patients with no AF, Group B (n = 11) – patients with new onset AF postoperatively and Group C (n = 9) – patients with preoperative history of atrial fibrillation. The serum levels of PTX3, CRP, TLR2, IL-8, IL-18, sFas, MMP-7 and MMP-8 were measured at the following time points: before surgery, immediately and 6 h after surgery and on the 1st, 3rd and 7th postoperative days (POD). Results: Serum levels of PTX3 showed a significant difference between Groups A and C on the 3rd POD (p<0.05) and on the 7th POD (p<0.0001). IL-8 levels were different between Groups A and C immediately after surgery (p<0.05), 6 hours after surgery (p<0.05) and on the 3rd POD (p<0.05). There was a difference between Groups B and C on the 1st POD in IL-8 levels (p<0.05). The sFas levels differed between Groups A and C on the 3rd POD (p<0.01) and the 7th POD (p<0.05). There was also a difference on the 7th POD (p<0.05) between the Groups B and C. No significant differences between the groups was seen for other biomarkers. Conclusion: This study demonstrates significantly different dynamics of PTX3, IL-8 and sFas levels after cardiac surgery in relation to AF.

Download Full-text

Was the atrioventricular block similar in anterior and inferior ST-elevation myocardial infarction?

EP Europace ◽

10.1093/europace/euab116.322 ◽

2021 ◽

Vol 23 (Supplement_3) ◽

Author(s):

H Santos ◽

M Santos ◽

I Almeida ◽

H Miranda ◽

C Sa ◽

...

Keyword(s):

Myocardial Infarction ◽

Atrial Fibrillation ◽

Logistic Regression ◽

Atrioventricular Block ◽

St Elevation Myocardial Infarction ◽

Group A ◽

St Elevation ◽

Artery Disease ◽

Group B ◽

New Onset

Abstract Funding Acknowledgements Type of funding sources: None. OnBehalf Portuguese Registry of Acute Coronary Syndromes Background The presence of atrioventricular block (AVB) in ST-elevation myocardial infarction (STEMI) is more frequently registered when is identified in the inferior leads. However, AVB maybe occurs in anterior STEMI, yet the AVB and STEMI localization maybe had different implications. Objective Evaluate the impact and prognosis of AVB according to the STEMI localization. Methods Multicenter retrospective study, based on the Portuguese Registry of Acute Coronary Syndrome between 1/10/2010-3/05/2020. Patients were divided into two groups: A – patients with anterior STEMI, and B – patients with inferior STEMI. Were excluded patients without a previous cardiovascular history or clinical data regarding AVB occurrence. Logistic regression was performed to assess AVB as a prognostic marker in STEMI patients. Results From 32157 patients, was identified 462 with AVB, 72 in group A (15.6%) and 390 in group B (84.4%). Both groups were similar regarding gender (p = 0.710), age (p = 0.068), body mass index (p = 0.535), admitly directly to cat lab (p = 0.635), initial symptons until first medical contact (p = 0.561), smoker status (p = 0.483), diabetes mellitus (p = 0.331), coronary artery disease (p = 0.053), previous stroke (p = 0.332), peripheral artery disease (p = 0.348), chronic kidney disease (p = 0.425), systolic blood pressure (p = 0.057), multivessel diasease (p = 0.235), new-onset of atrial fibrillation (p = 0.582), cardiac arrest (p = 0.062) and stroke complication (p = 0.685). Group B had higher left ventricular ejection fraction (LVEF) >50% (16.9 vs 60.7%, p < 0.001). On the other hand, group A had more arterial hypertension (79.7 vs 66.2%, p = 0.027), dislipidaemia (58.2 vs 54.4%, p = 0.038), heart rate at admission (81 ± 20 vs 59 ± 23, p < 0.001), Killip-Kimball class > I (45.7 vs 29.6%, p = 0.008), sinus rhythm at admission (84.5 vs 72.6%, p = 0.035), heart failure complication (65.3 vs 37.1%, p < 0.001), cardiogenic shock complication (42.3 vs 24.7%, p < 0.001), ACS mechanical complication (8.3 vs 3.1%, p = 0.047), sustained ventricular tachycardia during ACS hospitalization (19.4 vs 8.5%, p = 0.005) and hospitalization death (52.9 vs 44.7%, p < 0.001). Logistic regression revealed that AVB in inferior STEMI was a predictor of new-onset of atrial fibrillation (odds ratio (OR) 3.817, p = 0.038, confidence interval (CI) 1.123-12.975), with a R2 Nagelkerke 24.4. Also, revealed that AVB in anterior STEMI was a predictor of death (OR 0.111, p < 0.001, CI 0.034-0.366), with a R2 Nagelkerke 55.2. Conclusions AVB in inferior STEMI was a predictor of new-onset of atrial fibrillation and AVB in anterior STEMI was a predictor of death.

Download Full-text

Prognosis of new-onset of atrial fibrillation in acute coronary syndrome: Portuguese experience

EP Europace ◽

10.1093/europace/euab116.180 ◽

2021 ◽

Vol 23 (Supplement_3) ◽

Author(s):

H Santos ◽

M Santos ◽

I Almeida ◽

H Miranda ◽

C Sa ◽

...

Keyword(s):

Heart Failure ◽

Atrial Fibrillation ◽

Mortality Rates ◽

The Other ◽

Coronary Syndrome ◽

Group A ◽

One Year ◽

Group B ◽

New Onset

Abstract Funding Acknowledgements Type of funding sources: None. OnBehalf Portuguese Registry of Acute Coronary Syndromes Background Acute coronary syndrome (ACS) and atrial fibrillation (AF) are common diseases in developed countries and in some cases, the first episode of AF can occur during the ACS. A stressful event like an ACS can be a trigger for AF, being important to realize its impact and prognosis in the short and long term. Objective Evaluate the impact and prognosis of new-onset AF in ACS. Methods Multicenter retrospective study, based on the Portuguese Registry of ACS between 1/10/2010-4/09/2019. Patients were divided into two groups: A – patients without new-onset AF, and B – patients that presented new onset of AF. Were excluded patients without a previous cardiovascular history or clinical data during the admission and the follow-up period. Logistic regression was performed to assess if new-onset AF in ACS was a predictor of major adverse cardiac events and mortality. Kaplan-Meier test was performed to establish the survival rates and re-admission for one year of follow up. Results 9687 patients suffered ACS and had follow-up at 1 year, 9264 in group A (95.6%) and 423 in group B (4.4%). Both groups were similar regarding dyslipidemia, diabetes mellitus, previous coronary artery disease, multivessel disease after the cardiac catheterization. Group A had more smokers (28.2 vs 17.8%, p < 0.001) and left ventricular ejection fraction (LVEF) >50% (69.2 vs 45.1%, p < 0.001). On the other hand, group B was elderly (67 ± 14 vs 75 ± 12, p < 0.001), female (26.9 vs 34.0%, p < 0.001), arterial hypertension (70.5 vs 77.5%, p = 0.005), was more admitted directly to the cat lab (12.5 vs 17.7%, p = 0.002), ST-segment elevation myocardial infarction (40.2 vs 49.9%, p < 0.001), Killip-Kimball classification > I (12.8 vs 34.8%, p < 0.001) and hybrid revascularization (0.7 vs 2.4%, p = 0.002). Logistic regression revealed that new-onset of AF in ACS patients was a predictor of congestive heart failure (odds ratio (OR) 1.75, p < 0.001, confidence interval (CI) 1.47-2.09), cardiogenic shock (OR 3.08, p < 0.001, CI 2.37-4.01), sustained ventricular tachycardia (OR 2.29, p < 0.001, CI 1.61-3.25) and intrahospital mortality (OR 1.99, p < 0.001, CI 1.51-2.63). Nevertheless, new-onset of AF was not associated with re-infarction (p = 0.361), mechanical complications (p = 0.319), atrioventricular block (p = 0.574), stroke (p = 0.131) and cardiac arrest (p = 0.060) during the hospitalization for ACS. Mortality rates at one year of follow-up showed significant differences, p < 0.001, between the two groups (Figure 1). Similar results were found concerning re-admission for all causes, p = 0.021 (Figure 2), on the other causes, re-admission for cardiovascular causes do not reveal to be significant, p = 0.515. Conclusions New-onset of AF in ACS was a predictor of congestive heart failure, cardiogenic shock, sustained ventricular tachycardia and intrahospital mortality. AF was associated with higher mortality rates and re-admission for all causes at one year follow up.

Download Full-text

Dexamethasone Versus Ondansetron in Preventing Postoperative Nausea and Vomiting In Laparoscopic Surgery

Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University ◽

10.48036/apims.v17i3.512 ◽

2021 ◽

Vol 17 (3) ◽

pp. 222-226

Author(s):

Anum Malik ◽

Arshad Shahani ◽

Jawad Zahir ◽

Hassam Zulfiqar ◽

Tabassum Aziz

Keyword(s):

Postoperative Nausea ◽

Postoperative Nausea And Vomiting ◽

Nausea And Vomiting ◽

P Value ◽

Inclusion Criteria ◽

Significant Difference ◽

Quasi Experimental ◽

Group A ◽

The Mean ◽

Group B

Objective: To compare the efficacy of dexamethasone 8mg versus ondansetron 4mg in preventing postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy Methodology: This quasi-experimental study was conducted at the Department of Anaesthesia and Intensive Care, Holy Family Hospital from 29th July 2018 to 28th January 2019. Anesthesia was induced with propofol (2mg/kg IV) and Atracurium (0.5 mg/kg IV) was given to facilitate tracheal intubation. Nalbuphine (0.2mg/kg) was used as analgesic.Patients were randomly divided into two groups. Patients in Group A received 4mg ondansetron at end of surgery and Group B received 8mg dexamethasone at induction. Results: A total of 90 patients were included according to the inclusion criteria of the study. The mean age (years) in the study was 37.11+10.60 years. Frequency and percentage of nausea (up to 24 hours) among both the groups was 28 (62.2) and 28 (62.2) respectively (p-value = 1.0) while the frequency and percentage of vomiting (within 24 hours after extubation) was 28 (62.2) and 27 (60.0) respectively (p-value = 0.829) Conclusion: The study concluded that there was no significant difference dexamethasone and ondansetron in preventing postoperative nausea and vomiting.

Download Full-text

Effect of Intraoperative Loading Dose of Amiodarone for Prophylaxis Against Atrial Fibrillation in Patients with Rheumatic Valvular Heart Disease Undergoing Valve Replacement Surgery

Cardiovascular Journal ◽

10.3329/cardio.v12i2.47986 ◽

2020 ◽

Vol 12 (2) ◽

pp. 102-108

Author(s):

Romena Rahman ◽

AM Asif Rahim ◽

AYM Shahidullah ◽

QM Anisujjaman ◽

ASM Iftekher Hossain ◽

...

Keyword(s):

Atrial Fibrillation ◽

Sinus Rhythm ◽

Valve Replacement ◽

Normal Sinus Rhythm ◽

Loading Dose ◽

Replacement Surgery ◽

Normal Sinus ◽

Group A ◽

Group B ◽

Valve Replacement Surgery

Background: Atrial Fibrillation (AF) is the most common arrhythmia occurring after cardiac surgery and its peak incidence is between second or third postoperative day. It occurs in 40% to 50% of patients after valve surgery alone or combined valve and CABG surgery respectively. Among all the anti-arrhythmic drugs evaluated for AF, amiodarone has shown the most promising results with successful conversion and maintenance of normal sinus rhythm achieved in 50%–70% of patients. Methods: Sixty diabetic patients purposively selected who underwent isolated off pump coronary artery bypass procedure in NICVD. Group A – 30 patients receiving loading dose of amiodarone intra-operatively before establishment of CPB during valve replacement surgery and Group B- 30 patients without receiving loading dose of amiodarone intra-operatively during valve replacement surgery. Incidence of atrial fibrillation in postoperative period was evaluated. Results: Atrial fibrillation was observed in 8 (26.7%) patients in group A and 18 (60%) patients in group B (p=0.009). Ventricular tachycardia developed in 6.7% patients in group B and none in group A (p=0.47). Mean duration of ICU stay was 2.04±0.30 days in Group A and Group B was 2.98±0.77 days (p=0.03). Mean duration of post-operative stay was 7.20±0.66 days in Group A and Group B was 7.85±0.60 days (p=0.10). Conclusion: A single intra operative dose of intravenous amiodarone increases the incidence of conversion of AF to normal sinus rhythm. When AF persisted, use of amiodarone reduces the frequency of need for cardioversion and the energy required for it. Cardiovasc. j. 2020; 12(2): 102-108

Download Full-text

A Comparative Clinical Study of Khanda Shunthi and Prasarni Avleha in the Management of Amavata with Special Reference to Rheumatoid Arthritis

International Journal of Ayurveda and Pharma Research ◽

10.47070/ijapr.v9isuppl1.2026 ◽

2021 ◽

pp. 20-26

Author(s):

Anu Gupta ◽

Kalpana Patni

Keyword(s):

Comparison Group ◽

Adult Population ◽

Research Work ◽

P Value ◽

Inclusion Criteria ◽

Significant Difference ◽

Comparative Clinical Study ◽

Group A ◽

Group B ◽

Walking Time

Background: Amavata is the most common form of inflammatory arthopathy seen in India. Among adult population below the age of 50 years this is the most common form of arthritis. For the present study, on Amavata as shaman therapy, Khanda Shunthi and Prasarni Avleha the Ushnaveeryadravya medicaments were chosen. Aims & Objective: The present research work aimed at to evaluate efficacy and establish safe use of Khanda Shunthi and Prasarni Aavaleha in Amavata. Materials & Methods: 40 subjects of Amavata fulfilling the inclusion criteria were selected from OPD and IPD of Desh Bhagat Ayurvedic Hospital, Mandi Gobindgarh, Punjab and randomly divided into two groups, group A and B, comprising each of 20 patients. Group-A subjects received Khanda Shunthi for 60 days, Group-B subjects received Prasarni Avaleha for 60 days. Assessments were done on 0th and 60th day of treatment. Results and Conclusions: In both the groups, highly significant results were observed in all the cardinal parameters with P value for fever and Hb are greater than 0.05 hence there is no significant difference in effect of Group A and Group B on fever and Hb. P values for all other symptoms are less than 0.05 hence we conclude that there is significant difference in effect of group A and group B on pain, swelling, stiffness, fever, ESR, walking time and grip strength. On comparison group A treatment is more effective than group B for all assessment criteria.

Download Full-text

Conduction and voltage characteristics associated with new-onset postoperative atrial fibrillation

EP Europace ◽

10.1093/europace/euab116.118 ◽

2021 ◽

Vol 23 (Supplement_3) ◽

Author(s):

MS Van Schie ◽

D Veen ◽

RK Kharbanda ◽

R Starreveld ◽

YJHJ Taverne ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cardiac Surgery ◽

Low Voltage ◽

Postoperative Atrial Fibrillation ◽

P Value ◽

Atrial Remodeling ◽

Conduction Disorders ◽

The Right ◽

Af Recurrence ◽

New Onset

Abstract Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): CVON-AFFIP [grant number 914728], NWO-Vidi [grant number 91717339] Background Postoperative atrial fibrillation (PoAF) is the most common complication encountered after cardiac surgery, with incidences ranging from 20-80% depending on the type of procedure. Still, pathophysiological mechanisms underlying development of PoAF remain partially unclear. It is generally accepted that PoAF requires both a trigger and a susceptible atrial substrate for genesis and maintenance of the arrhythmia. The transition from early PoAF (E-PoAF) to late PoAF (L-PoAF) is considered to progress from a trigger-driven to a more substrate-driven disease. Therefore, development of L-PoAF is more likely to occur in patients with more extensive pre-existing substrate at time of surgery. Particularly in patients with new-onset PoAF, whom lack AF induced remodeling, characterization of the atrial substrate could aid in our understanding of PoAF development. Purpose To examine 1) severity of conduction disorders as well as voltage characteristics, such as low-voltage areas (LVAs), 2) to compare these characteristics between patients without and with new-onset PoAF, and 3) to establish whether it predicts progression to L-PoAF within five years after cardiac surgery. Methods Intra-operative epicardial mapping (interelectrode distance 2mm) of the right and left atrium (RA, LA), Bachmann’s Bundle (BB) and pulmonary vein area (PVA) was performed during SR in 263 patients (27 male, 67 ± 11 years) with new-onset PoAF. Unipolar electrograms were used to define potential amplitudes, LVAs, conduction velocity (CV) and the amount of conduction disorders. A p-value <0.05 was considered statistically significant. Results 37% of the patients developed new-onset PoAF within the first days after surgery. These patients had significantly slower CV at BB (90.9[82.5–99.4] vs. 87.0[75.5–95.1] cm/s) and more conduction disorders at BB and PVA (6.10[3.83–9.09] vs. 7.26[4.53–11.19] % and 4.26[2.55–6.24] vs. 4.78[3.12–7.50] %) compared to those who remained in SR. In addition, compared to the SR group, voltages in PoAF patients were particularly lower at BB, PVA and LA (5.70[3.82–7.80] vs. 4.53[2.52–6.85] mV, 4.21[2.41–6.55] vs. 3.62[1.94–5.65] mV and 5.79[3.85–7.62] vs. 4.89[3.23–7.10] mV), while more LVAs were found at all defined atrial regions. These differences were even more dominantly present in patients with AF recurrence after a period of new-onset E-PoAF. This transition to L-PoAF could even occur 5 years after surgery and was only found in patients who also developed E-PoAF. Conclusions Patients who develop new-onset PoAF already have substantial signs of atrial remodeling prior to cardiac surgery compared to those who remained in SR. Additionally, patients who had AF recurrence after new-onset PoAF have even more extensive signs of atrial substrate, and AF recurrence can even occur up to 5 years after surgery. Therefore, in patients with new-onset PoAF, rhythm monitoring should carefully be performed in the years after cardiac surgery. Abstract Figure.

Download Full-text

TO COMPARE THE EFFICACY OF LABETALOL AND METHYLDOPA IN TREATMENT OF PREGNANCY INDUCED HYPERTENSION

10.36106/gjra/0710001 ◽

2020 ◽

pp. 54-55

Author(s):

Ashish Yadav ◽

Rohitash Kularia ◽

Subash Chandra ◽

Anita Sharma

Keyword(s):

Antihypertensive Drugs ◽

Pregnancy Induced Hypertension ◽

Inclusion Criteria ◽

Hypertension In Pregnancy ◽

Induced Hypertension ◽

Group A ◽

The Mean ◽

Group B ◽

Labour Room ◽

New Onset

Background- The present study is undertaken with limited available facilities to find out the efficacy of two oral antihypertensive drugs namely labetalol and methyldopa in management of pregnancy induced hypertension. Methods- The study consisted of 100 patients with pregnancy induced hypertension attending outpatient department and admitted in ANW, or who directly came to labour room. These patients were randomly selected on lottery basis after they fulfilled the inclusion criteria. Total 100 patients were taken for the study and divided into 2 groups of 50 patients in each group. Results- The mean SBP before treatment in methyldopa group was161.33 ± 8.97 mmHg and 160.03 ± 8.23 mmHg in labetalol group which showed a fall to 138.61 ± 6.67 mmHg (methyldopa group) and 138.08 ± 5.37 mmHg (labetalol groups) after treatment. Fall of SBP was significant in both the groups. But inter group difference was not significant (p > 0.05). The mean DBP before treatment was 106.85 ± 4.33 mmHg in methyldopa group and 105.63 ± 5.23 mmHg in labetalol group which decreased to 89.31 ± 6.51 mmHg and 89.68 ± 5.26 mmHg respectively after treatment. Fall of DBP was significant in both the groups. But inter group difference was not significant (p > 0.05). Fall of MAP was significant in Group A and Group B. But inter group difference was not significant (p > 0.05). Conclusion-Labetalol and methyldopa are equally efficacious in controlling blood pressure in new onset hypertension in pregnancy.

Download Full-text